In a welcome move, Edwards Lifesciences saw its Relative Strength Rating rise from 67 to 71 on Friday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest runs. See if Edwards Lifesciences can continue to show renewed price strength and hit that benchmark.
While now is not an ideal time to jump in, see if the stock is able to establish and enter a buying range in heavy volume.
Earnings growth rose last quarter from 7% to 16%, but sales fell from 9% to 6%.
The company holds the No. 12 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
